Federal Register Notice: FDA has determined the regulatory review period for Schering Corp.’s Noxafil (posaconazole) is 3,650 days for extending a patent which claims that human drug product. Noxafil is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft versus host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy. To view this notice, click here.